MedTrace Logo

Study Effect of VIA-2291 on Vascular Inflammation

NCT00358826 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 191

Last updated 2012-07-23

Study results available
· View outcomes & findings →

Summary

This is a dose ranging study to compare the effect of VIA-2291 vs. Placebo on various inflammatory biomarkers in patients with recent acute coronary events

Conditions

Interventions

DRUG

VIA-2291

oral dosing, 1 time daily for 12 or 24 weeks

DRUG

Placebo

oral dosing, 1 time daily for 12 or 24 weeks

Sponsors & Collaborators

  • Montreal Heart Institute

    collaborator OTHER

  • Tallikut Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Rebecca Taub, MD · VIA Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2008-08-31
Completion
2008-09-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00358826 on ClinicalTrials.gov